Tariffs

AstraZeneca to List Shares in New York but Keep London Base

AstraZeneca said its global listing will broaden its investor base and boost its appeal for shareholders.
AstraZeneca to List Shares in New York but Keep London Base
The logo for AstraZeneca outside its North America headquarters in Wilmington, Del., on Mar. 22, 2021. Rachel Wisniewski/Reuters
Evgenia Filimianova
|Updated:
0:00

AstraZeneca announced on Sept. 29 that it will list its ordinary shares directly on the New York Stock Exchange, replacing its American depository receipts, but said it is not abandoning London.

AstraZeneca, the UK’s second-biggest listed company with a market value of 170 billion pounds ($228 billion), said the change is part of a plan to “harmonise” its listing structure across London, Stockholm, and New York, making it easier for investors to trade its stock globally.

Evgenia Filimianova
Evgenia Filimianova
Author
Evgenia Filimianova is a UK-based journalist covering a wide range of international stories, with a particular interest in foreign policy, economy, and UK politics.